Obesity-drug developer BioAge Labs Inc. held on to a slim gain at the closing bell and natural-gas producer BKV Corp. ended flat Thursday, the day the two initial public offerings debuted.

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human ...

Earlier this week, BioAge said in a filing it was looking to offer 10.5M shares priced between $17 and $19 per share.The ...

BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of shares on offer by 40%. The expansion of the listing reflects the massive ...

Kristen Fortney, cofounder and CEO of BioAge Labs. From the San Francisco Business Times. BioAge Labs Inc., which has turned its aging diseases focus toward the hot area of obesity drugs ...

Investing.com -- BioAge Labs, a clinical-stage biotech company developing therapies for metabolic diseases, has attracted attention from Wall Street investment banks, with three analysts ...

Citi analyst Samantha Semenkow initiated coverage of BioAge Labs (BIOA) with a Buy rating and $45 price target BioAge is a clinical-staged biotech focused on advancing therapies for metabolic ...

BioAge Labs, Inc. (BIOA) has received a new Buy rating, initiated by Morgan Stanley analyst, Jeffrey Hung. Jeffrey Hung’s rating is based on several promising developments at BioAge Labs, Inc ...

RICHMOND, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic ...

RICHMOND, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases ...